Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
Phathom Pharmaceuticals (NASDAQ: PHAT) appointed Sanjeev Narula as Chief Financial and Business Officer on October 6, 2025. Mr. Narula is described as experienced in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, mergers & acquisitions, and operations.
Management says the hire strengthens leadership as Phathom executes its growth strategy, targets profitability, and commercializes VOQUEZNA, which the company says is gaining traction.
Phathom Pharmaceuticals (NASDAQ: PHAT) ha nominato Sanjeev Narula come Chief Financial and Business Officer (Responsabile Finanziario e degli Affari) il 6 ottobre 2025. Il signor Narula viene descritto come esperto nel far crescere aziende biopharma in fase commerciale, con competenze in strategie di capitale e investitori, fusioni e acquisizioni e operazioni.
La direzione afferma che l’assunzione rafforza la leadership mentre Phathom mette in atto la sua strategia di crescita, punta alla redditività e commercializza VOQUEZNA, che l’azienda dice sta guadagnando terreno.
Phathom Pharmaceuticals (NASDAQ: PHAT) nombró a Sanjeev Narula como Director Financiero y de Negocios (CFO y Chief Business Officer) el 6 de octubre de 2025. El Sr. Narula se describe como con experiencia en escalar empresas biofarmacéuticas en etapa comercial, con experiencia en estrategias de capital e inversores, fusiones y adquisiciones y operaciones.
La dirección dice que la contratación fortalece el liderazgo mientras Phathom ejecuta su estrategia de crecimiento, apunta a la rentabilidad y comercializa VOQUEZNA, que la empresa dice que está ganando tracción.
Phathom Pharmaceuticals (NASDAQ: PHAT)는 Sanjeev Narula를 최고재무책임자 겸 비즈니스 책임자로 임명했습니다(2025년 10월 6일). Narula 씨는 상업 단계 바이오제약 회사를 확장하는 데 경험이 있으며 자본 및 투자자 전략, 인수 합병, 운영에 대한 전문성을 가지고 있는 것으로 소개됩니다.
경영진은 이 채용이 Phathom의 성장 전략 실행, 수익성 목표, VOQUEZNA의 상용화에 따라 리더십을 강화한다고 말합니다. 회사는 VOQUEZNA가 주목을 받고 있다고 밝혔습니다.
Phathom Pharmaceuticals (NASDAQ: PHAT) a nommé Sanjeev Narula au poste de Directeur Financier et Affaires (Chief Financial and Business Officer) le 6 octobre 2025. M. Narula est décrit comme ayant une expérience dans le scale-up d’entreprises biopharmaceutiques en phase commerciale, avec une expertise dans les stratégies de capital et d’investisseurs, les fusions et acquisitions, et les opérations.
La direction affirme que cette embauche renforce le leadership alors que Phathom met en œuvre sa stratégie de croissance, vise la rentabilité et commercialise VOQUEZNA, qui, selon l’entreprise, gagne en traction.
Phathom Pharmaceuticals (NASDAQ: PHAT) ernannte Sanjeev Narula zum Chief Financial and Business Officer am 6. Oktober 2025. Herr Narula wird als erfahren beschrieben, wie man kommerzielle Biopharma-Unternehmen in der Skalierung unterstützt, mit Fachkenntnissen in Kapital- und Investorenstrategien, Fusionen und Übernahmen sowie im operativen Geschäft.
Das Management sagt, dass die Einstellung die Führung stärkt, während Phathom seine Wachstumsstrategie umsetzt, Profitabilität anvisiert und VOQUEZNA kommerzialisiert, das laut dem Unternehmen an Zugkraft gewinnt.
Phathom Pharmaceuticals (NASDAQ: PHAT) عينت Sanjeev Narula كرئيس مالي وشريك أعمال (Chief Financial and Business Officer) في 6 أكتوبر 2025. يوصف السيد نارولا بأنه ذو خبرة في توسيع شركات الأحياء الدوائية في المرحلة التجارية مع خبرة في استراتيجيات رأس المال والمستثمرين، والاندماج والاستحواذ، والعمليات.
وتقول الإدارة إن التعيين يعزز القيادة بينما تنفذ Phathom استراتيجيتها للنمو وتستهدف الربحية وتقوم بتسويق VOQUEZNA، وتقول الشركة إن VOQUEZNA تكتسب زخماً.
Phathom Pharmaceuticals (NASDAQ: PHAT) 任命 Sanjeev Narula 为首席财务及业务官（Chief Financial and Business Officer），日期为 2025年10月6日。Narula 先生被描述为在将商业阶段生物制药公司推向规模化方面具有经验，专长包括资本与投资者策略、并购与运营。
管理层表示，此次任命将加强领导力，帮助 Phathom 在执行增长战略、追求盈利并商业化 VOQUEZNA 的过程中取得进展，公司称 VOQUEZNA 正在获得牵引力。
- New CFBO appointment announced on October 6, 2025
- Hire brings commercial-stage scaling and M&A experience
- Focus on profitability and shareholder-value execution emphasized
- No financial targets or guidance disclosed with the appointment
- No quantified timeline for profitability or VOQUEZNA growth provided
- Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellence
- Appointment strengthens Phathom’s leadership team and ability to execute its growth strategy in GI
FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer.
“We welcome Sanjeev to Phathom’s leadership team at this important stage of our growth,” said Steve Basta, President and Chief Executive Officer of Phathom. “His extensive financial and operational expertise will be critical as we execute our strategy to achieve profitability and drive long-term shareholder value.”
Mr. Narula commented, “This is an exciting moment to join Phathom, with VOQUEZNA gaining traction and a clear path for continued growth. I look forward to working with the talented team to drive financial performance and help unlock the company’s full potential.”
About Sanjeev Narula
Sanjeev Narula most recently served as Chief Financial Officer at Intra-Cellular Therapies, where he oversaw finance leading up to its
During his 16 years at Pfizer, he held senior finance roles, including CFO for Pfizer’s Essential Health Business and CFO of the Primary Care Business Unit, then the company’s largest commercial division. Earlier in his career, he held leadership positions at American Express and Xerox.
Mr. Narula earned his bachelor’s degree in accounting and economics from the University of Delhi and is a Chartered Accountant from the Institute of Chartered Accountants of India.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com follow on LinkedIn and X.
Forward Looking Statement
This press release contains forward-looking statements, including without limitation statements regarding: our strategy, plans and expectations as to future profitability, growth, performance, and shareholder value. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: we may not achieve results from the commercialization of VOQUEZNA at the levels we expect; the market opportunity for VOQUEZNA may be significantly smaller than our expectations; market acceptance for VOQUEZNA from healthcare professionals, patients, and payors in the indications for which it is approved may be significantly lower than we anticipate; we may encounter coverage, reimbursement, market access, or other issues in the course of our commercialization efforts that may negatively impact our efforts and results; the size of the market opportunity and unmet need for new treatment options may not be as high as we anticipate; our results may be negatively impacted by the launch of competitive products; we may experience adverse impact as the result of our dependence on third parties in connection with supply chain and product manufacturing; we may be negatively impacted by regulatory developments or other governmental actions in the United States, including government healthcare reform; we may encounter unexpected adverse side effects or inadequate efficacy of VOQUEZNA that may limit or impair market acceptance, or may result in recalls, withdrawals or product liability claims; if we were to breach our license agreement with Takeda for vonoprazan, Takeda might take action, including termination, that would significantly impair our business; our operating expenses may be higher than we anticipate, including if we decide to engage in activities not currently in our plan or if we face unexpected, or higher than anticipated, expenses, including as the result of unexpected events such as litigation; depending on our results and activities, we may not achieve growth or profitability on the timelines we expect or at all; and any of the foregoing or other factors may negatively impact our ability to achieve our plans, goals, mission, vision and potential. For additional discussion of these and other risks, see the risk disclosure in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this presentation to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
Who is Sanjeev Narula and why did Phathom (PHAT) hire him on October 6, 2025?
How does the Sanjeev Narula appointment affect Phathom's (PHAT) strategy to reach profitability?
What did Phathom say about VOQUEZNA in the October 6, 2025 announcement?
When did Phathom (PHAT) announce the new chief financial and business officer?
Will Sanjeev Narula's appointment cause immediate financial changes for PHAT shareholders?
Where is Phathom Pharmaceuticals headquartered as of the October 6, 2025 release?
